Mwandishi
Mhariri:
Imeboreshwa:
ULY CLINIC
ULY CLINIC
Jumanne, 14 Julai 2026, 23:07:34 UTC
Emphysema management
Emphysema
Emphysema is a destructive process involving the gas-exchanging air spaces of the lungs that results in perforations, obliteration of airspace walls, and coalescence of small distinct airspaces into much larger ones, leading to enlargement of the gas-exchanging units of the lungs.
These changes cause loss of elastic recoil of the lungs and abnormal gas exchange.
Clinical presentation
Shortness of breath
Cough, sometimes caused by the production of mucus
Wheezing
Slow and prolonged expiration
Chest wall hyperinflation
Limited diaphragmatic motion on auscultation
Distant breath sounds and heart sounds
Coarse early inspiratory crackles
Use of accessory muscles
Pursed-lip breathing
Signs of cor pulmonale:
Raised JVP
Peripheral oedema
Hepatomegaly
Other features of right heart failure
Cyanosis
Asterixis
Investigations
Haematocrit:
Men >52%
Women >47%
OR
FBP (look at haematocrit)
ABG (look for elevated bicarbonate/metabolic alkalosis)
CXR
Sputum culture and microbial sensitivity
Pulmonary function tests
Six-minute walk test
CT scan of the chest/HRCT (for evaluation for lung volume reduction surgery)
Non-pharmacological treatment
Stop smoking.
Give oxygen after evaluation.
Pharmacological treatment
Inhaled bronchodilators relax and open the airways.
They may be:
Short-acting bronchodilators
Albuterol
Ipratropium
Long-acting bronchodilators
Salmeterol
Tiotropium
These medicines may be available as inhalers ("puffers") or as solutions for nebulization.
A nebulizer machine aerosolizes the bronchodilator solution, which is then breathed through a tube.
For more details, refer to treatment in Section 9.2 above.
Table: COPD staging and recommended therapies
GOLD stage (FEV1) | Exacerbations per year | Mild symptoms | Moderate/Severe symptoms |
Stage I (≥80%) | ≤2 | Group A: Bronchodilator (SABA PRN) | Group B: LAMA or LABA |
Stage II (50–79%) | ≤2 | Group A: Bronchodilator (SABA PRN) | Group B: LAMA or LABA |
Stage III (30–49%) | ≥2 | Group C: LAMA + LABA | Group D: LAMA or LAMA + LABA or ICS + LABA |
Stage IV (<30%) | ≥2 | Group C: LAMA + LABA | Group D: LAMA or LAMA + LABA or ICS + LABA |
Abbreviations
FEV1 = Forced Expiratory Volume in 1 second
SABA = Short-Acting Beta-Agonist
LABA = Long-Acting Beta-Agonist
LAMA = Long-Acting Muscarinic Antagonist
ICS = Inhaled Corticosteroid
HRCT = High-Resolution Computed Tomography
ABG = Arterial Blood Gas
CXR = Chest X-ray
FBP = Full Blood Picture
JVP = Jugular Venous Pressure
Imeandikwa:
Jumatatu, 22 Juni 2026, 11:22:51 UTC
References:
